In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

The vaccine and a dominant variant may not match this year, which combined with low vaccine rates could make for a severe flu ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

The mRNA platform offers the advantage of faster vaccine production, which could allow more time to decide on which flu strains to cover.

Flu cases are rising in eastern Pennsylvania and both St. Luke’s and LVHN are seeing some patients present to the hospital ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

The experimental mRNA vaccine prevented 60% to 67% of flu infections, while the conventional vaccine prevented 44% to 54% of ...

Study shows high-dose vaccines work better for older adults while cell-based versions benefit younger people as respiratory ...

Mutations to some H3N2 strains might be mismatched to the current flu vaccine, but doctors explain why it’s still a good idea ...

For people younger than 65, U.S.-licensed flu vaccines had an estimated effectiveness of 44% to 54% that season. Among those ...

A Fredericton-based pharmacist says people are still showing up to get vaccinated for influenza, despite recent news that ...

Flu vaccines are crucial tools in protecting public health by reducing the risk of influenza illness and its complications.